Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific - Seite 2

• Leverage solubilization intellectual property from our partnership with Altus Formulation;
• Develop patent protected inhalation Rx drugs based on Tetra IP;
• Established supply agreements for GMP grade cannabinoids with several suppliers;
• Established collaborations with manufacturers capable of synthetic commercial pharmaceutical production;
• Leverage licensed technology from Vitiprints LLC for clinical trial supply and commercial scale production capacity to meet global demand. 
• Internal core capabilities include research and development, regulatory affairs, pharmaceutical drug and device compliance, clinical trial operations;
• Initiated the preparation for commercialization of prescription drugs. 

“Tetra is set for a strong future moving forward and is clearly shaped into a Biopharmaceutical Company of Rx products based on cannabinoid-based drug discovery and development," stated Dr. Guy Chamberland, CEO and CRO.

About MAKScientific
MAKScientific is a privately held Boston-based company founded in 2004 on the basis of research by Professor Alexandros Makriyannis in the chemistry and biochemistry of the cannabinoid system. The Company is a leader in cannabinergic compound development with the ability to address major unmet medical needs for selected diseases with a clear competitive advantage over present therapies. Our mission is the discovery, development and commercialization of novel therapeutics that modulate the endocannabinoid system: a key regulator of homeostasis.

MAKScientific has extensive expertise in the endocannabinoid biochemical pathways and has validated therapeutic targets. These include two known GPCRs (CB1 and CB2) as well as enzymes that are in the modulation of this biochemical system including fatty acid amide hydrolase (FAAH), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL), and monoacylglyceral lipase (MGL) as well as the cannabinoid transporter system. The Company has proficiency in medicinal chemistry and drug design and has substantial drug development assets that include a large library of carefully designed druggable cannabinergic compounds as well as advanced preclinical drug candidates for treating metabolic disorders, chronic liver disease, pain, neurodegenerative, inflammatory diseases and addiction.